A large U.S.-led cooperative group trial coordinated by Mayo Clinic found no survival benefit from extending lenalidomide maintenance beyond two years in standard-risk multiple myeloma. The ECOG-ACRIN ENDURANCE study results address a longstanding question about whether “continuous” maintenance therapy meaningfully improves outcomes once a patient has already remained progression-free for an extended period. The randomized evidence, published in the New England Journal of Medicine, suggests clinicians may be able to reduce long-term treatment exposure without sacrificing overall survival in this risk group. The findings are likely to influence practice discussions about duration, patient quality of life, and cumulative toxicity. For the myeloma community, the study also provides a clearer evidence anchor for sequencing and de-escalation strategies after initial response. It may also reshape how future maintenance trials define stop rules. Overall, ENDURANCE contributes directly to treatment optimization by testing a pragmatic duration cutoff rather than only escalating dose intensity.